Patents by Inventor Richard Mulligan

Richard Mulligan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10611064
    Abstract: There is provided a mold apparatus and process whereby a warhead body can be fabricated in a single over molding process which may also include therein metal fragments, metal balls, obturators, boat tails and other aerodynamic features, metal rings and/or threads. Other molds and processes are presented whereby a warhead body may be over molded in a polymer matrix in sequential steps which may include adding therein metal balls, then fragments, and any of obturators, boat tails and other aerodynamic features, metal rings and/or threads, as desired. Still another process for fabricating a warhead body is presented whereby an insert section is first preloaded with metal fragments and covered with a skin, then the insert section is inserted into an oversized area in a mold, and polymer is then loaded around the insert section to form a unitary warhead body.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: April 7, 2020
    Assignee: The United States of America as Represented by the Secretary of the Army
    Inventors: Daniel Lee Prillaman, Leon Moy, Viral Panchal, Richard Wu, Patrick Mark, Kevin Mulligan, Jesse Sunderland, James Grassi, Jason Wasserman
  • Publication number: 20190163902
    Abstract: A data processing apparatus comprises branch prediction circuitry adapted to store at least one branch prediction state entry in relation to a stream of instructions, input circuitry to receive at least one input to generate a new branch prediction state entry, wherein the at least one input comprises a plurality of bits; and coding circuitry adapted to perform an encoding operation to encode at least some of the plurality of bits based on a value associated with a current execution environment in which the stream of instructions is being executed. This guards against potential attacks which exploit the ability for branch prediction entries trained by one execution environment to be used by another execution environment as a basis for branch predictions.
    Type: Application
    Filed: October 2, 2018
    Publication date: May 30, 2019
    Inventors: Alastair David REID, Dominic Phillip MULLIGAN, Milosch MERIAC, Matthias Lothar BOETTCHER, Nathan Yong Seng CHONG, Ian Michael CAULFIELD, Peter Richard GREENHALGH, Frederic Claude Marie PIRY, Albin Pierrick TONNERRE, Thomas Christopher GROCUTT, Yasuo ISHII
  • Publication number: 20190151475
    Abstract: In certain embodiments, the disclosure relates to compositions and methods relating to a translation-based gene regulation system that functions in mammalian cells. In certain specific embodiments, the disclosure relates to methods of regulating gene expression via modulating translation termination.
    Type: Application
    Filed: November 27, 2018
    Publication date: May 23, 2019
    Inventors: Richard Mulligan, George J. Murphy
  • Patent number: 10233447
    Abstract: In certain embodiments, the disclosure relates to compositions and methods relating to a ribozyme-based gene regulation system that functions in mammalian cells. In certain specific embodiments, the disclosure relates to schistosome self-cleaving RNA mutant motifs.
    Type: Grant
    Filed: January 3, 2017
    Date of Patent: March 19, 2019
    Assignee: The Children's Medical Center Corporation
    Inventors: Richard Mulligan, Laising Yen
  • Patent number: 10159754
    Abstract: In certain embodiments, the disclosure relates to compositions and methods relating to a translation-based gene regulation system that functions in mammalian cells. In certain specific embodiments, the disclosure relates to methods of regulating gene expression via modulating translation termination.
    Type: Grant
    Filed: January 8, 2013
    Date of Patent: December 25, 2018
    Assignee: The Children's Medical Center Corporation
    Inventors: Richard Mulligan, George J. Murphy
  • Publication number: 20170253872
    Abstract: In certain embodiments, the disclosure relates to compositions and methods relating to a ribozyme-based gene regulation system that functions in mammalian cells. In certain specific embodiments, the disclosure relates to schistosome self-cleaving RNA mutant motifs.
    Type: Application
    Filed: January 3, 2017
    Publication date: September 7, 2017
    Applicant: The Children s Medical Center Corporation
    Inventors: Richard Mulligan, Laising Yen
  • Publication number: 20150056174
    Abstract: In certain embodiments, the disclosure relates to compositions and methods relating to a ribozyme-based gene regulation system that functions in mammalian cells. In certain specific embodiments, the disclosure relates to schistosome self-cleaving RNA mutant motifs.
    Type: Application
    Filed: May 14, 2012
    Publication date: February 26, 2015
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Richard Mulligan, Laising Yen
  • Publication number: 20140044684
    Abstract: In certain embodiments, the disclosure relates to compositions and methods relating to a translation-based gene regulation system that functions in mammalian cells. In certain specific embodiments, the disclosure relates to methods of regulating gene expression via modulating translation termination.
    Type: Application
    Filed: January 8, 2013
    Publication date: February 13, 2014
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Richard Mulligan, George J. Murphy
  • Patent number: 8586100
    Abstract: Described herein are methods for purifying hematopoietic stem cells. Also described herein are methods for purifying EPCR+ cells. The invention also provides substantially pure isolated hematopoietic stems cells, including EPCR+ hematopoietic stem cells.
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: November 19, 2013
    Assignee: Children's Medical Center Corporation
    Inventors: Alejandro Balazs, Richard Mulligan
  • Publication number: 20120121552
    Abstract: Described herein are methods for purifying hematopoietic stem cells. Also described herein are methods for purifying EPCR+ cells. The invention also provides substantially pure isolated hematopoietic stems cells, including EPCR+ hematopoietic stem cells.
    Type: Application
    Filed: November 17, 2011
    Publication date: May 17, 2012
    Applicant: Children's Medical Center Corporation
    Inventors: Alejandro Balazs, Richard Mulligan
  • Patent number: 8088585
    Abstract: Described herein are methods for purifying hematopoietic stem cells. Also described herein are methods for purifying EPCR+ cells. The invention also provides substantially pure isolated hematopoietic stems cells, including EPCR+ hematopoietic stem cells.
    Type: Grant
    Filed: October 29, 2004
    Date of Patent: January 3, 2012
    Assignee: Children's Medical Center Corporation
    Inventors: Alejandro Balazs, Richard Mulligan
  • Publication number: 20110061120
    Abstract: In certain embodiments, the disclosure relates to compositions and methods relating to a ribozyme-based gene regulation system that functions in mammalian cells. In certain specific embodiments, the disclosure relates to schistosome self-cleaving RNA mutant motifs.
    Type: Application
    Filed: March 1, 2010
    Publication date: March 10, 2011
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Richard Mulligan, Laising Yen
  • Publication number: 20090304641
    Abstract: In certain embodiments, the disclosure relates to compositions and methods relating to a translation-based gene regulation system that functions in mammalian cells. In certain specific embodiments, the disclosure relates to methods of regulating gene expression via modulating translational termination.
    Type: Application
    Filed: October 17, 2006
    Publication date: December 10, 2009
    Applicant: CHILDREN'S HOSPITAL BOSTON
    Inventors: Richard Mulligan, George J. Murphy
  • Publication number: 20070141038
    Abstract: Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof. Further disclosed are chimeric restriction endonucleases.
    Type: Application
    Filed: December 8, 2006
    Publication date: June 21, 2007
    Inventors: Andre Choulika, Richard Mulligan
  • Publication number: 20070134208
    Abstract: Described herein are methods for purifying hematopoietic stem cells. Also described herein are methods for purifying EPCR+ cells. The invention also provides substantially pure isolated hematopoietic stems cells, including EPCR+ hematopoietic stem cells.
    Type: Application
    Filed: October 29, 2004
    Publication date: June 14, 2007
    Applicant: Children's Medical Center Corporation
    Inventors: Alejandro Balazs, Richard Mulligan
  • Publication number: 20060269529
    Abstract: Modified T lymphocytes that express a chimeric T cell receptor reactive with two or more different cell surface angiogenic marker are disclosed. The modified T lymphocytes are useful in methods in controlling angiogenesis and in therapeutic methods in controlling tumor growth.
    Type: Application
    Filed: May 7, 2003
    Publication date: November 30, 2006
    Inventors: Thomas Niederman, Zoher Ghogawala, Bos Carter, Richard Mulligan
  • Publication number: 20060084093
    Abstract: Novel packaging cell lines useful for generating viral accessory protein independent HIV-derived retroviral vector particles, methods of constructing such packaging cell lines and methods of using the viral accessory protein independent HIV-derived retroviral vector particles are disclosed.
    Type: Application
    Filed: August 16, 2005
    Publication date: April 20, 2006
    Inventors: Jeng-Shin Lee, John Gray, Richard Mulligan
  • Publication number: 20060014669
    Abstract: The present invention provides a method for inhibiting undesired angiogenesis including tumor-associated angiogenesis. The invention further provides a method for increasing the number of red blood cells or hematocrit in the circulation in subjects in need thereof. The invention also provides a method for simultaneously treating low hematocrit and undesired angiogenesis. Additionally, the present invention provides a method for determining efficacy or endpoint of treatment with one or more VEGF-inhibitors.
    Type: Application
    Filed: June 15, 2005
    Publication date: January 19, 2006
    Applicants: CHILDREN'S MEDICAL CENTER CORPORATION, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Calvin Kuo, Richard Mulligan
  • Publication number: 20050158741
    Abstract: In certain embodiments, the disclosure relates to compositions and methods relating to a ribozyme-based gene regulation system that functions in mammalian cells. In certain specific embodiments, the disclosure relates to schistosome self-cleaving RNA mutant motifs.
    Type: Application
    Filed: November 15, 2004
    Publication date: July 21, 2005
    Applicant: Children's Hospital
    Inventors: Richard Mulligan, Laising Yen
  • Publication number: 20040132675
    Abstract: The present invention provides a method for inhibiting undesired angiogenesis including tumor-associated angiogenesis. The invention further provides a method for increasing the number of red blood cells or hematocrit in the circulation in subjects in need thereof. The invention also provides a method for simultaneously treating low hematocrit and undesired angiogenesis. Additionally, the present inventio provides a method for determining efficacy or endpoint of treatment with one or more VEGF-inhibitors.
    Type: Application
    Filed: February 10, 2004
    Publication date: July 8, 2004
    Inventors: Calvin Kuo, Richard Mulligan